GGrantIndex
← Leaderboards

Ctr For Molecular Medicine/Immunology

Belleville, NJ

Compare ↔
$22,933,906
Total funding
54
Grants

Funding over time

peak $4.2M · FY2005–14
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$22,933,906 · 54

By mechanism

R01$16,532,487 · 14
P01$3,378,657 · 27
R21$1,911,882 · 5
C06$505,510 · 1
R56$248,879 · 1
S10$131,490 · 1

Investigators at Ctr For Molecular Medicine/Immunology

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Robert M Sharkey$6,337,3566 gr2David V Gold$3,826,5443 gr3Rosalyn D Blumenthal$3,706,0534 gr4Rhona N Stein$2,156,1583 gr5Myron S Czuczman$1,773,3411 gr6M Jules Mattes$1,099,7502 gr7Jack D Burton$775,2593 gr8David M Goldenberg$459,0064 gr

Largest grants

RADIOIMMUNOTHERAPY OF CANCER$3,346,153
P01 · FY2000 · CA
MANAGEMENT OF CANCER WITH MONOCLONAL ANTIBODIES$2,430,562
P01 · FY2000 · CA
Targeted Therapy of B-cell Malignancies$1,618,062
P01 · FY2008 · CA
Targeted Therapy of B-cell Malignancies$1,616,000
P01 · FY2005 · CA
Targeted Therapy of B-cell Malignancies$1,604,348
P01 · FY2006 · CA
Targeted Therapy of B-cell Malignancies$1,603,282
P01 · FY2007 · CA
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP$1,006,461
R01 · FY2005 · CA
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP$977,147
R01 · FY2004 · CA
PRE-CLINICAL COMBINATION CHEMO/RADIOANTIBODY THERAPY$948,718
R01 · FY2002 · CA
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP$922,425
R01 · FY2003 · CA
RAIT of Pancreatic Cancer with Humanized PAM4$886,058
R01 · FY2005 · CA
RAIT of Pancreatic Cancer with Humanized PAM4$866,940
R01 · FY2004 · CA
RAIT of Pancreatic Cancer with Humanized PAM4$624,927
R01 · FY2003 · CA
Bispecific Antibody Pretargeting for Therapy$582,397
R01 · FY2009 · CA
Targeted Therapy of B-cell Malignancies$519,832
P01 · FY2009 · CA
Bispecific Antibody Pretargeting for Therapy$512,569
R01 · FY2008 · CA
CONSTRUCTION OF A MONOCLONAL ANTIBODY SUPPORT FACILITY$505,510
C06 · FY2000 · RR
Bispecific Antibody Pretargeting for Therapy$477,990
R01 · FY2007 · CA
IMPROVED SECOND ANTIBODY RADIOIMMUNOTHERAPY OF CANCER$442,644
R01 · FY2000 · CA
RADIOIMMUNOTHERAPY OF NONHODGKINS LYMPHOMA WITH LL2$435,005
R01 · FY2000 · CA